Study of Galectin-3 Levels and Risk of Post-Operative Atrial Fibrillation After Coronary Artery Bypass Surgery

What this Trial Is About

This research aims to explore the relationship between high levels of Galectin-3 and the risk of developing post-operative atrial fibrillation after isolated coronary artery bypass grafting CABG. It also evaluates whether elevated Galectin-3 levels are linked to other post-operative complications and major adverse cardiovascular events. The study is observational and includes patients undergoing CABG surgery. Participants will be enrolled during their preoperative evaluation. A peripheral blood sample will be taken within 24 hours before the CABG surgery to measure Galectin-3 levels. Patients will then be followed daily during hospitalization and through three follow-up appointments after discharge, for a total follow-up period of 12 months. During the study, researchers will monitor whether participants develop atrial fibrillation within 7 days after surgery and assess other complications at 6 weeks. They will also track major cardiovascular events and changes in the hearts left atrium structure over 12 months. The study involves blood sample collection, health assessments during hospital stay, and scheduled follow-up visits to gather comprehensive outcome data.

Association Between GalectiN-3 and POSt-operative AtrIal Fibrillation After Coronary Artery BypaSs Graft